CN104284663A - 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途 - Google Patents

高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途 Download PDF

Info

Publication number
CN104284663A
CN104284663A CN201380022530.XA CN201380022530A CN104284663A CN 104284663 A CN104284663 A CN 104284663A CN 201380022530 A CN201380022530 A CN 201380022530A CN 104284663 A CN104284663 A CN 104284663A
Authority
CN
China
Prior art keywords
laquinimod
methods according
multiple sclerosis
human patients
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380022530.XA
Other languages
English (en)
Chinese (zh)
Inventor
丹·巴-佐哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104284663(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to CN201610240473.8A priority Critical patent/CN105832733A/zh
Publication of CN104284663A publication Critical patent/CN104284663A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380022530.XA 2012-05-02 2013-05-01 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途 Pending CN104284663A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610240473.8A CN105832733A (zh) 2012-05-02 2013-05-01 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02
US61/641,389 2012-05-02
PCT/US2013/039090 WO2013166166A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610240473.8A Division CN105832733A (zh) 2012-05-02 2013-05-01 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途

Publications (1)

Publication Number Publication Date
CN104284663A true CN104284663A (zh) 2015-01-14

Family

ID=49514859

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380022530.XA Pending CN104284663A (zh) 2012-05-02 2013-05-01 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途
CN201610240473.8A Pending CN105832733A (zh) 2012-05-02 2013-05-01 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610240473.8A Pending CN105832733A (zh) 2012-05-02 2013-05-01 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途

Country Status (21)

Country Link
US (3) US20130303569A1 (OSRAM)
EP (1) EP2844255A4 (OSRAM)
JP (2) JP2015515985A (OSRAM)
KR (1) KR20150013658A (OSRAM)
CN (2) CN104284663A (OSRAM)
AR (1) AR090885A1 (OSRAM)
AU (1) AU2013256352A1 (OSRAM)
BR (1) BR112014027010A2 (OSRAM)
CA (1) CA2870684A1 (OSRAM)
CL (1) CL2014002935A1 (OSRAM)
EA (1) EA201492010A1 (OSRAM)
HK (1) HK1206246A1 (OSRAM)
IL (1) IL235337A0 (OSRAM)
MX (1) MX2014013039A (OSRAM)
PE (1) PE20150161A1 (OSRAM)
PH (1) PH12014502447A1 (OSRAM)
SG (1) SG11201406594UA (OSRAM)
TW (2) TW201804997A (OSRAM)
UY (1) UY34775A (OSRAM)
WO (1) WO2013166166A1 (OSRAM)
ZA (1) ZA201408820B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112437665A (zh) * 2018-07-20 2021-03-02 默克专利有限公司 用于治疗及预防多发性硬化症的方法中的经取代氨基-嘧啶化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. POLMAN ET AL: "Treatment with laquinimod reduces development of active MRI lesions in relapsing MS", 《NEUROLOGY》 *
SUSAN JEFFREY: "Laquinimod Slows Progression in MS: ALLEGRO Published", 《MEDSCAPE MEDICAL NEWS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112437665A (zh) * 2018-07-20 2021-03-02 默克专利有限公司 用于治疗及预防多发性硬化症的方法中的经取代氨基-嘧啶化合物

Also Published As

Publication number Publication date
CN105832733A (zh) 2016-08-10
CA2870684A1 (en) 2013-11-07
JP2017222691A (ja) 2017-12-21
HK1206246A1 (en) 2016-01-08
PE20150161A1 (es) 2015-02-22
SG11201406594UA (en) 2014-11-27
US20150265592A1 (en) 2015-09-24
EP2844255A4 (en) 2015-10-14
JP2015515985A (ja) 2015-06-04
US20160000775A1 (en) 2016-01-07
AR090885A1 (es) 2014-12-10
CL2014002935A1 (es) 2015-03-06
MX2014013039A (es) 2015-02-04
KR20150013658A (ko) 2015-02-05
ZA201408820B (en) 2016-06-29
IL235337A0 (en) 2014-12-31
US20130303569A1 (en) 2013-11-14
PH12014502447A1 (en) 2015-01-12
AU2013256352A1 (en) 2014-11-27
UY34775A (es) 2013-11-29
TW201347762A (zh) 2013-12-01
BR112014027010A2 (pt) 2017-06-27
WO2013166166A1 (en) 2013-11-07
EA201492010A1 (ru) 2015-06-30
TW201804997A (zh) 2018-02-16
EP2844255A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
CN104284663A (zh) 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途
DK2442651T3 (en) Treatment of multiple sclerosis with laquinimod
JP2017095476A (ja) 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用
US20160296511A1 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
CN103781355A (zh) 用拉喹莫德与干扰素-β的组合治疗多发性硬化症
US9662322B2 (en) Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
HK1224555A1 (en) Use of high dose laquinimod for treating multiple sclerosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150114